2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura
Journal of Thrombosis and Haemostasis · 2025-11 · 23 (11) · 3711-3732
DOI: 10.1016/j.jtha.2025.06.002 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-11. Verfasst von X Long Zheng und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA; Institute of Reproductive Medicin…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 133 Literaturangaben. Gefördert von: NHLBI NIH HHS, NHLBI.
Abstract (Originalsprache)
BACKGROUND: Over the past few years, new information has emerged in the management of both immune thrombotic thrombocytopenic purpura (iTTP) and congenital (or hereditary) thrombotic thrombocytopenic purpura (cTTP). METHODS: In March 2024, the International Society on Thrombosis and Haemostasis (ISTH) formed a multidisciplinary panel comprising hematologists, intensivists, nephrologists, pathologists, patient representatives, and a methodology team. The panel discussed all treatment questions related to thrombotic thrombocytopenic purpura (TTP) using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method to appraise evidence and formulate recommendations. RESULTS: For patients with cTTP in remission, a new strong recommendation was issued for the use of recombinant ADAMTS-13 over fresh frozen plasma in the context of moderate certainty evidence. The panel also revised a previous recommendation and suggested using fresh frozen plasma over a watch-and-wait approach for patients with cTTP in remission based on very low certainty evidence should recombinant. The panel reviewed and referenced new publications supporting therapeutic efficacy, potential survival benefit, and cost considerations of adding caplacizumab to therapeutic plasma exchange, corticosteroids, and rituximab, but concluded that no change was warranted to the previous recommendations in the management of iTTP. Good practice statements on the concomitant use of antithrombotic agents were marginally modified. CONCLUSIONS: For patients with iTTP, no change to 2020's recommendations. For patients with cTTP, the panel supports ADAMTS-13 replacement. Where accessible, recombinant ADAMTS-13 provides the most favorable balance of benefits and risks. Otherwise, fresh frozen plasma may still be effective. Shared decision-making should include the benefits, the potential harms, and the burden of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, Kansas, USA; Institute of Reproductive Medicine and Developmental Sciences, The University of Kansas Medical Center,…
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada; Department of Hematology, University Medical City, Muscat, Oman.
- Department of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Centre de Référence des Microangiopathies Thrombotiques, Service d'Hématologie, Hôpital Saint-Antoine, Assistance Publique, Hôpitaux de Paris, Sorbonne Université, Paris, France.
- School of Professional Studies, Columbia University, New York, USA.
- Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, Ontario, Canada; Clinical Epidemiology and Research Center, IRCCS…
Förderung
- NHLBI NIH HHS
- NHLBI
Zitieren
APA
Zheng, X. L., Al-Housni, Z., Cataland, S. R., Coppo, P., Geldziler, B., Germini, F., Iorio, A., Keepanasseril, A., Masias, C., Matsumoto, M., McCrae, K. R., McIntyre, J., Mustafa, R. A., Peyvandi, F., Russell, L., Tarawneh, R., Vesely, S. K., & International Society on Thrombosis and Haemostasis (2025). 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 23(11), 3711-3732. https://doi.org/10.1016/j.jtha.2025.06.002
Vancouver
Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, et al. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis. 2025;23(11):3711-3732. doi:10.1016/j.jtha.2025.06.002
BibTeX
@article{Zheng2025,
author = {Zheng, X Long and Al-Housni, Zainab and Cataland, Spero R and Coppo, Paul and Geldziler, Brian and Germini, Federico and Iorio, Alfonso and Keepanasseril, Arun and Masias, Camila and Matsumoto, Masanori and McCrae, Keith R and McIntyre, Jo and Mustafa, Reem A and Peyvandi, Flora and Russell, Lene and Tarawneh, Rawan and Vesely, Sara K and International Society on Thrombosis and Haemostasis, International Society on Thrombosis and Haemostasis},
title = {2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura},
journal = {Journal of Thrombosis and Haemostasis},
year = {2025},
volume = {23},
number = {11},
pages = {3711--3732},
doi = {10.1016/j.jtha.2025.06.002}
}
EUVIMED